Jonathan Fleming

SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many patient cell types to engineer what we believe can be a broad range of potential therapeutics. Our goal is to create well-tolerated cell therapies that can provide therapeutic benefit for patients and improve the patient experience over existing cell therapy approaches. With accelerated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, our approach could change the way people think about cell therapies. The company’s first therapeutic applications seek to generate target-specific immune responses, both in activation for the treatment of solid tumors and in immune tolerance for the treatment of unwanted immune reactions and autoimmune diseases.

CONTINUUS’ mission is to produce high-quality drugs that can be delivered to patients more effectively and at a lower cost. In achieving this goal, we look to radically transform the pharmaceutical manufacturing industry, steering it away from outdated batch systems to state-of-the-art continuous processes. CONTINUUS is leveraging a novel continuous manufacturing platform called Integrated Continuous Manufacturing (ICM), initially developed through an $85 M joint research project between Novartis and MIT. With ICM, we will improve affordability and accessibility of pharmaceuticals on a global scale. Our work is critical because the current manufacturing systems are time- and cost-inefficient, and are beset with quality problems. It is not unusual for manufacturing lead times, from start to finish, to be over one year, and studies have shown that the industry loses over $50 B annually due to wasteful processes. More importantly, these problems impact patient care. Hundreds of drugs are placed on the US FDA drug shortage website, many of which are life-saving (e.g., oncology drugs). To solve these problems, we offer a number of solutions: In addition, CONTINUUS is currently collaborating with hospital systems and pharmacy chains to establish its own generic business, where high-quality, low-cost drugs will be manufactured in the United States. To achieve our goals, CONTINUUS has assembled a team of talented engineers and scientists, with skills ranging from analytical chemistry to drug formulation. Rather than producing medicines through batch-wise, step-by-step processes, ICM allows for fully continuous and automated operations, where the synthesis of the active ingredient and the final dosage form are integrated into a seamless process. This novel method will allow “on-demand” manufacturing of pharmaceuticals, improving affordability and accessibility of pharmaceuticals on a global scale.

Q-State Biosciences is a discovery technology and therapeutics company based in Cambridge, MA, that combines advanced human cellular models, unique measurement engineering and AI / machine learning into a proprietary platform that enables novel discovery of optimized genetically targeted medicines for epilepsy, pain, and other diseases of the CNS.

Leerink Partners is now SVB Leerink. Follow us at: https://www.linkedin.com/company/svb-leerink

SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many patient cell types to engineer what we believe can be a broad range of potential therapeutics. Our goal is to create well-tolerated cell therapies that can provide therapeutic benefit for patients and improve the patient experience over existing cell therapy approaches. With accelerated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, our approach could change the way people think about cell therapies. The company’s first therapeutic applications seek to generate target-specific immune responses, both in activation for the treatment of solid tumors and in immune tolerance for the treatment of unwanted immune reactions and autoimmune diseases.

CONTINUUS’ mission is to produce high-quality drugs that can be delivered to patients more effectively and at a lower cost. In achieving this goal, we look to radically transform the pharmaceutical manufacturing industry, steering it away from outdated batch systems to state-of-the-art continuous processes. CONTINUUS is leveraging a novel continuous manufacturing platform called Integrated Continuous Manufacturing (ICM), initially developed through an $85 M joint research project between Novartis and MIT. With ICM, we will improve affordability and accessibility of pharmaceuticals on a global scale. Our work is critical because the current manufacturing systems are time- and cost-inefficient, and are beset with quality problems. It is not unusual for manufacturing lead times, from start to finish, to be over one year, and studies have shown that the industry loses over $50 B annually due to wasteful processes. More importantly, these problems impact patient care. Hundreds of drugs are placed on the US FDA drug shortage website, many of which are life-saving (e.g., oncology drugs). To solve these problems, we offer a number of solutions: In addition, CONTINUUS is currently collaborating with hospital systems and pharmacy chains to establish its own generic business, where high-quality, low-cost drugs will be manufactured in the United States. To achieve our goals, CONTINUUS has assembled a team of talented engineers and scientists, with skills ranging from analytical chemistry to drug formulation. Rather than producing medicines through batch-wise, step-by-step processes, ICM allows for fully continuous and automated operations, where the synthesis of the active ingredient and the final dosage form are integrated into a seamless process. This novel method will allow “on-demand” manufacturing of pharmaceuticals, improving affordability and accessibility of pharmaceuticals on a global scale.

Q-State Biosciences is a discovery technology and therapeutics company based in Cambridge, MA, that combines advanced human cellular models, unique measurement engineering and AI / machine learning into a proprietary platform that enables novel discovery of optimized genetically targeted medicines for epilepsy, pain, and other diseases of the CNS.

Leerink Partners is now SVB Leerink. Follow us at: https://www.linkedin.com/company/svb-leerink